Finland· FI-REL-REL5316

Isuprel

A isoprenaline product, registered in Finland by Sterling-Winthrop S.A.. The same ATC class is registered in 12 of our 19 countries.

ATC C01CA02

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedIsuprelATCC01CA02REGISTER NO.FI-REL-REL5316PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Isoprenaline is registered in 12 of 19 countries.

Countries holding a registration under ATC C01CA02 (isoprenaline), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 6 of them publish a price we can compare per daily dose

Isoprenaline · ATC C01CA02

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Ireland
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Manufacturer
Sterling-Winthrop S.A.
Country
Finland (FI)
ATC code
C01CA02
ATC class
Isoprenaline
Defined daily dose
90 mg, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

435 interactions on record for isoprenaline.

Graded by severity as the source publishes them — 64 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Isoprenaline · interactions on record

435 records

  • 64 severe
  • 347 moderate
  • 24 minor

Most severe, free to view

  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • QuinidineC01BA01severe
  • ProcainamideC01BA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bba123e3-f96a-4f6d-b6bb-2e056c0fd2e2
GET /v1/drugs/bba123e3-f96a-4f6d-b6bb-2e056c0fd2e2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "90",
  "form": "injektioneste",
  "route": null,
  "ddd_unit": "mg",
  "strength": "0.2 mg/ml",
  "atc_label": "isoprenaliini",
  "ma_number": "10242",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL5316",
  "authorised_at": "1990-06-06"
}

See everything about isoprenaline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.